Drug Trial Radar · NCT01095003
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
770
Actual
Start
May 2009
Primary completion
Dec 2011
Study completion Oct 2015
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents. Options for the treatment of patients who have progressed after an anthracycline and a taxane are limited. The high level of in-vitro synergy of vinflunine combined with 5-fluorouracil (5-FU) together with the good tolerance and the encouraging response rate observed while combining IV vinflunine to oral capecitabine make it a promising combination to investigate further in a phase III trial. This phase III trial will evaluate the effectiveness and the safety profile of such combination for the treatment of patient with advanced breast cancer previously treated with or resistant to anthracycline and taxane resistant.
Conditions
- Breast Cancer
Interventions
Vinflunine plus CapecitabineDrug
Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
CapecitabineDrug
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: Baseline up to 2 years 7 months
Locations
110 sites in 21 countries. Site status is shown where the registry gives one.
Site not named
Buenos Aires, Argentina
Site not named
Quilmes, Argentina
Site not named
Rosario, Argentina
Site not named
San Martin, Argentina
Site not named
San Miguel de Tucumán, Argentina
Site not named
Grodno, Belarus
Site not named
Homyel, Belarus
Site not named
Minsk, Belarus
Site not named
Vitebsk, Belarus
Site not named
Brussels, Belgium
Site not named
Liège, Belgium
Site not named
Curitiba, Brazil
Site not named
Porto Alegre, Brazil
Site not named
Santo André, Brazil
Site not named
São Paulo, Brazil
Site not named
Plovdiv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Stara Zagora, Bulgaria
Site not named
Brno, Czechia
Site not named
Jihlava, Czechia
Site not named
Tallinn, Estonia
Site not named
Angers, France
Site not named
Caen, France
Site not named
Dijon, France
Site not named
Le Mans, France
Site not named
Lorient, France
Site not named
Lyon, France
Site not named
Montpellier, France
Site not named
Nantes, France
Site not named
Saint-Brieuc, France
Site not named
Saint-Cloud, France
Site not named
Saint-Herblain, France
Site not named
Tours, France
Site not named
Villejuif, France
Site not named
Budapest, Hungary
Site not named
Székesfehérvár, Hungary
Site not named
Szolnok, Hungary
Site not named
Bangalore, India
Site not named
Bhopal, India
Site not named
Calicut, India
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.